Getinge Group Interim Report January

Reporting period January – June

  · Order intake rose by 3.8% to SEK 12,483 M (12,025), and grew organically by
3.7%
  · Net sales increased by 7.6% to SEK 11,680 M (10,858), and grew organically
by 7.0%
  · Profit before tax was SEK 878 M (1,285)
  · Net profit totalled SEK 641 M (951)
  · Earnings per share amounted to SEK 2.67 (3.98)
  · EBITA before restructuring declined by 4.1% to SEK 1,797 M (1,873).
Adjusted for exchange-rate effects and the tax on medical-technical products
introduced in the US, EBITA rose by 9.7%

Reporting period April – June

  · Order intake rose by 4.6% to SEK 6,515 M (6,230), and grew organically by
5.4%
  · Net sales increased by 7.2% to SEK 6,015 M (5,612), and grew organically by
7.3%
  · Profit before tax was SEK 626 M (716).
  · EBITA before restructuring declined by 1.5% to SEK 1,004 M (1,019).
Adjusted for exchange-rate effects and the tax on medical-technical products
introduced in the US, EBITA rose by 10.9%

Second quarter 2013

Order intake improved during the period and the potential for the Group to
achieve an organic growth exceeding that of the preceding year has increased.
Although the product and market mix were challenging during the quarter, when
adjusted for the negative exchange-rate fluctuations and the recently introduced
tax on medical-technical products in the US, operating profit improved to a
satisfactory degree.

Teleconference with CEO Johan Malmquist and CFO Ulf Grunander

11 July 2013 at 10:00 a.m. Swedish time

Sweden: +46 (0) 8 5065 3937
UK: +44 (0) 20 3427 1910
Code: 5923551

GETINGE GROUP is a leading global provider of products and systems that
contribute to quality enhancement and cost efficiency within healthcare and life
sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and
MAQUET. ArjoHuntleigh focuses on patient mobility and wound management
solutions. GETINGE provides solutions for infection control within healthcare
and contamination prevention within life sciences. MAQUET specializes in
solutions, therapies and products for surgical interventions, interventional
cardiology and intensive care.

The information is such that Getinge AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.
Getinge Group Interim Report January - June 2013

Pièces jointes
